Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
Xin Miao(Johnson & Johnson (United States)), Honghui Zhou(Janssen (United States)), Yuki Iwaki, Danièle Ouellet(Janssen (United States)), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Kristy Kemmerer(Janssen (United States)), Alfred L. Garfall(University of Pennsylvania), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Yan Xu(University of California, Berkeley), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Yang Chen(Janssen (United States)), Lixia Pei(Janssen (United States)), Liviawati S. Wu(Janssen (United States)), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Yaming Su(Janssen (United States)), Amrita Krishnan(City of Hope), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 5
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Serum amyloid A, the major vertebrate acute‐phase reactant
|European Journal of Biochemistry|1999|1.1k